Apimeds Pharmaceuticals US (APUS) EPS (Basic) (2024 - 2025)
Apimeds Pharmaceuticals US (APUS) reported EPS (Basic) of -$0.08 for Q4 2025, down 100.0% on a YoY basis from $30024.0 billion in Q4 2024, and up 42.86% quarter-over-quarter from -$0.14 in Q3 2025.
Apimeds Pharmaceuticals US (APUS) EPS (Basic) (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US has reported EPS (Basic) for 2 years, with the latest figure at -$0.08 in Q4 2025.
- For the quarter ending Q4 2025, EPS (Basic) fell 100.0% year-over-year to -$0.08; the trailing twelve-month figure through Dec 2025 stood at -$0.53 (down 194.44% YoY), and the FY2025 full-year result was -$0.55, down 205.56% from the prior year.
- EPS (Basic) for Q4 2025 stood at -$0.08, up from -$0.14 in the prior quarter.
- The five-year high for EPS (Basic) was -$0.04 in Q4 2024, with the low at -$0.26 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 0.32 |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 1.42 |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 6.32 |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 0.02 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.97 |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 0.11 |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -0.40 |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -0.40 |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.83 |
| 10 | Apimeds Pharmaceuticals US | 13.93 Mn | 10.29 Mn | - | -0.08 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.08 |
| Sep 30, 2025 | -0.14 |
| Jun 30, 2025 | -0.26 |
| Mar 31, 2025 | -0.05 |
| Dec 31, 2024 | -0.04 |
| Sep 30, 2024 | -0.04 |
| Jun 30, 2024 | -0.06 |
| Mar 31, 2024 | -0.04 |